Overview
Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
Status:
Unknown status
Unknown status
Trial end date:
2015-11-01
2015-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by pancytopenia and hypoplastic bone marrow. Immunosuppressive treatment with antithymocyte globulin (ATG)and cyclosporine remain the standard regimen with response rates of 70% or more and excellent overall survival. However ,there are no clinical trials to illustrate the response and complete remission rate with different doses of ATG.And there are no data reported on children with SAA so far.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Chinese Academy of Medical Sciences
Criteria
Inclusion Criteria:- clinical diagnosis of childhood acquired severe aplastic anemia(SAA)
Exclusion Criteria:
- clinical diagnosis of no childhood acquired severe aplastic anemia(SAA)